In recent years, five therapies targeting the programmed cell death protein (PD-1) and programmed cell death ligand 1 (PD-L1) axis were approved for bladder cancer (9), improving prognosis in patients with advanced bladder cancer. This evidence concerns the gene CD274 and urinary bladder carcinoma.